Goldman Philanthropic Partnerships
Sample Partnership Letter

June 13, 2003                                                                                                   

By e-mail  

John Smith, MD
Innovation Cancer Center
175 State Ave.
Chicago, IL 60000 

Dear Dr. Smith: 

Thank you for taking the time to talk to me about a potential funding co-sponsorship between the Innovation Cancer Center (ICC) and the Goldman Philanthropic Partnerships (GPP).  Your institution is doing so many great things with a terrific supporting cast.  It is our hope that an association with GPP will just add one more item to an impressive list of ICC activities. 

I provided you with a very brief overview of the funding partnerships that we have established with Mayo Clinic, University of Arizona College of Medicine, the International Myeloma Foundation, and the Kidney Cancer Association.  All of these co-ventures share the same characteristics.  Our partner shares our desire to find a cure for disease.  Each partner is interested in using a small portion of an overall research budget to support very innovative, frontier research, the type of project that they might otherwise not be able to fund, but that they know could change the course of research and cure.  Each partner wants to maintain control over the solicitation and validation of the research, and to participate in the funding and management of the research.  And each partner is willing to rely on us to help them further these goals, without having to give us anything but a chance to partner. 

Just to make sure I explained how this would work with ICC, I’ll describe it again here. 

Co-sponsorship of innovative research 

  • GPP would enter into a simple co-sponsorship with ICC to co-fund one or more innovative research projects at ICC. 
  • Once we have an agreement in place, ICC would solicit specific innovative research proposals from its faculty that could have a significant and immediate impact on cancer or other catastrophic diseases. 
  • These research proposals would be reviewed, revised and then validated by ICC research advisors. 
  • ICC would forward to GPP those validated proposals the ICC research advisors thought were most promising and which met the GPP innovative research definition (see attached).
  • ICC would agree to fund at least 50% of the project through funds available at ICC, or by bringing in additional co-sponsors.
  • GPP science advisors would help us validate the ICC projects and select those projects that fit our model, and then GPP would agree to fund up to 50% of the project. 

Dr. Smith, there are many advantages to this type of partnership.  ICC can effectively double it’s funding for these types of projects, as we will be funding up to fifty percent.  ICC can expand its donor base through our solicitation of our donors to participate in these ICC co-ventures.  ICC can find support for new researchers looking to find a foothold, or support for senior researchers looking to validate a new idea.  ICC can fund a new category of innovative research that could have a huge impact on the cure for cancer, and have a partner in GPP willing to share the risk. 

I am available as needed to discuss this further with you and your development director at any time.  Please let me know how you wish to proceed.  I look forward to hearing from you soon.   

Sincerely,  

Dr. Bruce E. Bloom
Chief Science Officer
Goldman Philanthropic Partnerships
70 West Madison Street, Suite 1500  
Chicago, IL 60602
312-780-3440
Bruce@GoldmanPartnerships.org